- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07949045
Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology (EPIDOCAVILH)
Pilot Study for the Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology
In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.
Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.
In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: STEPHANIE NOEL
- Telefoonnummer: 0033549443083
- E-mail: stephanie.noel@chu-poitiers.fr
Studie Contact Back-up
- Naam: MAUD BRECHET
- Telefoonnummer: 0033549029991
- E-mail: MAUD.BRECHET@chu-poitiers.fr
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patient ≥ 18 years old.
- Consultation for treatment initiation (first-line or relapse) for gynecological, digestive, urological, or hematological cancer.
- Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
- Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
- Patient declaring having a general practitioner.
- Patient's general practitioner agreeing to participate in the study.
- Patient covered by the French social Security system or through a third party.
Non-Inclusion Criteria:
- Patient already receiving care for this pain from the reference pain center or supportive care team.
- Patient unable to understand, write, or speak French.
- Patient diagnosed with uncontrolled psychiatric disorders.
- Patient with chronic pain unrelated to cancer.
- Pain related to therapeutic procedures.
- Patient residing in a medicalized facility.
- Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
- Patient with a significant impairment of general condition (ECOG-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Early management of acute pain
Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP. Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary. Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms. |
Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of eligible patients that provide a consent to participate
Tijdsspanne: 1 day
|
Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent. |
1 day
|
|
Proportion of general pactitioner that confirmed their participation
Tijdsspanne: 2 days
|
General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation. |
2 days
|
|
Proportion of consultations with the general practitioner performed
Tijdsspanne: 28 days
|
Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed. |
28 days
|
|
Proportion of consultations at the hospital performed
Tijdsspanne: 28 days
|
Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed. |
28 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in pain severity after 28 days
Tijdsspanne: 28 days
|
Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain). |
28 days
|
|
Change in pain interference after 28 days
Tijdsspanne: 28 days
|
Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain). |
28 days
|
|
Change in quality of life after 28 days
Tijdsspanne: 28 days
|
Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life). |
28 days
|
|
Proportion of patients requiring a specific pain management
Tijdsspanne: 28 days
|
Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team. |
28 days
|
|
Global satisfaction of the patients
Tijdsspanne: 28 days
|
Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied") |
28 days
|
|
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
Tijdsspanne: 28 days
|
The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch |
28 days
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Neurologische manifestaties
- Ziekten van het zenuwstelsel
- Urogenitale neoplasmata
- Neoplasmata per site
- Mannelijke urogenitale ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Neurologische gedragsmanifestaties
- Perceptuele stoornissen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Neoplasmata
- Gastro-intestinale neoplasmata
- Urologische neoplasmata
- Agnosie
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Onderzoekstechnieken
- Epidemiologische methoden
- Therapeutica
- Gegevensverzameling
- Evaluatiemechanismen voor gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Volksgezondheid
- Milieu en volksgezondheid
- Gedragscontrole
- Immobilisatie
- Enquêtes en vragenlijsten
- Terughoudendheid, fysiek
Andere studie-ID-nummers
- EPIDOCAVILH
- 2026-A01683-48 (Andere identificatie: French Ethics Committee Number (ID-RCB))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .